Introduction: CAR T cells (antigenic chimeric receptor) are a new type of emergent treatment classified among adoptive cell transfer immunotherapies (ACT). This receptor will contribute to the detection of specific malignant antigens on the membrane of cancer cells and the destruction of these, which together with chemotherapy, allow an effective anti-tumor treatment. Objective: to review the new therapies with CAR T cells in the common lymphomas, besides exposing the main complications and new therapeutic uses . Methods: an exhaustive bibliographic review was carried out from December 2018 to June 2018 in databases such as Medline, Science Direct, Lilacs and Embase, with the search MeSH terms: lymphoma, immunotherapy, genetic engineering, T lymphocytes. Conclusion: there are numerous applications of which this type of immunotherapy is a participant, currently proposes a therapeutic revolution in which not only include hematological malignancies, but also in solid tumors, is undoubtedly a feat of genetic engineering and medicine.
|Título traducido de la contribución||Car T cells: Progress that passes the advances in the treatment of malignant hemopathies|
|Número de páginas||10|
|Publicación||Revista Cubana de Hematologia, Inmunologia y Hemoterapia|
|Estado||Publicada - 1 oct. 2018|
|Publicado de forma externa||Sí|
Nota bibliográficaPublisher Copyright:
© 2018, Editorial Ciencias Medicas. All rights reserved.
- CAR T
- Genetic engineering